# T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/t790m-selective-egfr-tki-combined-with-dasatinib-as-an-optimal-strategy-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Satomi Watanabe,Takeshi Yoshida,Hisato Kawakami,Naoki Takegawa,Junko Tanizaki,Hidetoshi Hayashi,Masayuki Takeda,Kimio Yonesaka,Junji Tsurutani,Kazuhiko Nakagawa |
| Citations | 29 |
| DOI | 10.1158/1535-7163.mct-17-0351 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://mct.aacrjournals.org/content/molcanther/16/11/2563.full.pdf |
| OpenAlex ID | https://openalex.org/W2745482716 |
| PMID | 28839001 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Satomi Watanabe](https://scholariq.org/researchers/satomi-watanabe/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.